REQUEST A REP

PHARMACOKINETIC (PK) SIMULATOR

Simulate the PK curve to visualize the aripiprazole plasma concentrations over time.

  1. SELECT INITIATION REGIMEN


    Patients may be given another dose strength of oral aripiprazole. Please see Prescribing Information for more information.
  2. CHOOSE ARISTADA DOSE AND INTERVAL




    • Select one
      • Day 1 – same day as initiation*
      • Day 3 – 2 days after initiation*
      • Day 5 – 4 days after initiation*
      • Day 7 – 6 days after initiation*
      • Day 10 – 9 days after initiation*

    *Initiation is defined as ARISTADA INITIO 675 mg + 30 mg oral aripiprazole.

VIEW PHARMACOKINETIC PROFILE

Go back to graph

SIMULATED ARIPIPRAZOLE PLASMA CONCENTRATIONS FOR ARISTADA INITIATION REGIMENS ACROSS SELECTED ARISTADA DOSING OPTIONS3,4

Median Aripiprazole Concentrations (ng/mL)

Dotted line indicates end
of oral supplementation

LEGEND: Turn visibility on and off to compare

Start over

Add Dose

Add Dose

Add Dose

Add Dose

Simulator for illustrative purposes only.

Please read the Prescribing Information for ARISTADA INITIO and ARISTADA, including Boxed Warning.

ARISTADA provides consistent and sustained medication levels throughout the dosing period1

  • With the addition of a single intramuscular injection of ARISTADA INITIO and 30 mg of oral aripiprazole at the time of the first ARISTADA dose, aripiprazole concentrations reach relevant levels within 4 days2
References: 1. Hard ML, Wehr AY, Sadler BM, Mills RJ, von Moltke L. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil [published online ahead of print June 11, 2018]. Eur J Drug Metab Pharmacokinet. doi:10.1007/s13318-018-0488-4. 2. ARISTADA INITIO [package insert]. Waltham, MA: Alkermes, Inc; 2018. 3. Data on file. Alkermes, Inc. 4. Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. CNS Drugs. 2017l;31(7):617-624.

See how consistent and sustained medication levels are made possible by LinkeRx® technology

Watch Science of ARISTADA video